Clear Harbor Asset Management LLC Invests $1.66 Million in Baxter International Inc. $BAX

Clear Harbor Asset Management LLC bought a new stake in Baxter International Inc. (NYSE:BAX) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 78,009 shares of the medical instruments supplier’s stock, valued at approximately $1,663,000.

Several other institutional investors also recently made changes to their positions in the stock. Imprint Wealth LLC bought a new stake in shares of Baxter International in the 3rd quarter worth approximately $27,000. Basepoint Wealth LLC bought a new position in Baxter International during the 4th quarter worth $26,000. MUFG Securities EMEA plc acquired a new stake in Baxter International in the second quarter worth $46,000. Los Angeles Capital Management LLC acquired a new stake in Baxter International in the fourth quarter worth $46,000. Finally, Versant Capital Management Inc increased its position in Baxter International by 552.2% in the second quarter. Versant Capital Management Inc now owns 2,413 shares of the medical instruments supplier’s stock worth $51,000 after buying an additional 2,043 shares during the period. 90.19% of the stock is owned by institutional investors.

Baxter International Trading Down 0.2%

Shares of NYSE:BAX opened at $26.37 on Friday. The company has a 50 day moving average of $23.62 and a 200-day moving average of $20.36. The firm has a market cap of $13.63 billion, a P/E ratio of -12.74, a P/E/G ratio of 3.98 and a beta of 0.60. Baxter International Inc. has a twelve month low of $15.73 and a twelve month high of $30.00. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 1.39.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Baxter International had a negative net margin of 9.27% and a positive return on equity of 16.57%. The business had revenue of $2.96 billion for the quarter, compared to analyst estimates of $2.80 billion. During the same quarter last year, the business earned $0.59 earnings per share. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. As a group, analysts anticipate that Baxter International Inc. will post 2.04 earnings per share for the current fiscal year.

Baxter International Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Shareholders of record on Friday, August 28th will be paid a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date of this dividend is Friday, August 28th. Baxter International’s dividend payout ratio (DPR) is presently -1.93%.

Baxter International News Roundup

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Higher earnings forecasts: Zacks Research raised its FY2026 EPS estimate to $2.02 from $1.83 and its FY2027 estimate to $2.00 from $1.90. The FY2026 forecast is close to the broader consensus estimate of $2.04, suggesting improving expectations for Baxter’s profitability.
• Positive Sentiment: Several quarterly upgrades: Zacks increased its estimates for Q1 2027 EPS to $0.42 from $0.38, Q2 2027 EPS to $0.47 from $0.40, and Q2 2028 EPS to $0.51 from $0.45. These revisions indicate stronger projected earnings in multiple future periods.
• Neutral Sentiment: Analyst stance remains cautious: Despite the higher full-year estimates, Zacks maintained a “Hold” rating on BAX. The research firm’s FY2028 EPS forecast of $2.11 was also slightly reduced from $2.13, while its Q3 2027 and Q4 2026 estimates were trimmed to $0.52 and $0.60, respectively.
• Negative Sentiment: Reported cybersecurity incident: A report alleges that the ShinyHunters hacking group leaked 7.1 million Baxter International records. If confirmed, the incident could create legal, remediation, regulatory and reputational costs, although the available report does not specify the type or sensitivity of the exposed information. ShinyHunters Leaks 7.1 Million Baxter International Records

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Weiss Ratings raised shares of Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, July 31st. Citigroup raised shares of Baxter International from a “sell” rating to a “neutral” rating and increased their price objective for the stock from $17.00 to $28.00 in a report on Friday, July 31st. Zacks Research upgraded shares of Baxter International from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Wells Fargo & Company boosted their target price on shares of Baxter International from $19.00 to $23.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. Finally, TD Cowen upped their target price on shares of Baxter International from $20.00 to $24.00 and gave the stock a “hold” rating in a research report on Monday, July 27th. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Baxter International presently has an average rating of “Hold” and an average target price of $22.45.

Baxter International Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.